System-independent quantitative cardiac CT perfusion

系统独立的定量心脏 CT 灌注

• 批准号: 10154267
• 负责人: DEBASHISH ROY
• 金额: $ 96.26万
• 依托单位: BIOINVISION, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10154267
• 关键词: 3-Dimensional; Accident and Emergency department; Affect; Algorithms; Anatomy; Angiography; Attention; Biomedical Engineering; Blood flow; Calibration; Cardiac; Cardiac Volume; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Chest Pain; Clinical; Clinical Data; Computer software; Confidence Intervals; Coronary; Coronary Angiography; Coronary artery; Cost Savings; Data; Decision Making; Detection; Development; Diabetes Mellitus; Diagnostic; Diffuse; Disease; Dose; Electrocardiogram; Environment; Evaluation; Family suidae; Heart; Image; Imaging Phantoms; Imaging Techniques; Intervention; Iodine; Ischemia; Lead; Licensing; Machine Learning; Magnetic Resonance Imaging; Manufacturer Name; Maps; Measurement; Medical center; Methods; Microvascular Dysfunction; Modality; Myocardial; Obesity; Partner in relationship; Pathway interactions; Patient risk; Patients; Performance; Perfusion; Persons; Phase; Physiological; Positron-Emission Tomography; Prevalence; Process; Publications; Publishing; Research; Resolution; Roentgen Rays; Role; Sales; Scanning; Small Business Innovation Research Grant; Standardization; Stenosis; Stents; System; Testing; Therapeutic Intervention; Time; Tissues; Universities; University Hospitals; Vendor; Woman; X-Ray Computed Tomography; blood flow measurement; cardiovascular imaging; commercialization; coronary perfusion; cost; digital; improved; indexing; innovation; interest; performance tests; pre-clinical; prospective; prototype; research clinical testing; single photon emission computed tomography; software development; success; three-dimensional visualization; tool; trustworthiness; usability; virtual

System-independent quantitative cardiac CT perfusion Phase II, SBIR Summary BioInVision, Inc. and team - Case Western Reserve University (CWRU) biomedical engineers and University Hospitals Cleveland Medical Center (UH) imaging cardiologists - will develop software for quantitative analysis of cardiac CT perfusion (CCTP) data, creating an important tool for evaluation of cardiovascular disease. With this product, cardiologists will be able to identify functional flow deficits in coronary artery territories. When one combines functional myocardial blood flow (MBF) function with coronary anatomy from coronary computed to- mography angiography (CCTA), it provides needed information on the physiologic significance of a stenosis. The CCTP+CCTA combination could provide an ideal gateway exam for deciding whether to send a patient for percutaneous invasive coronary angiography and potential intervention (e.g., stenting). In addition, low flow with- out the presence of a stenosis suggests microvascular disease, a very prevalent ailment of growing concern, especially among women and diabetes patients. CT compares favorably to all other non-invasive cardiovascular imaging techniques (SPECT, PET, and MRI). It is available in many settings, including emergency departments, and is high throughput as compared to other methods. It provides both MBF and reliable coronary anatomy, with are unavailable in any other single modality, providing a unique ability to non-invasively discriminate cardiac microvascular disease. It has excellent resolution enabling detection of endocardial perfusion deficit, thought to be an early disease indicator that is impossible to assess with SPECT. CT is cheaper and has higher patient throughput than MRI or PET. With the inclusion of MBF, CT would have an excellent opportunity to disrupt the diagnostic pathway leading to percutaneous intervention, a pathway which has been dominated by SPECT my- ocardial imaging, a modality that gives zero information about coronary anatomy. To achieve reliable, accurate CT MBF measurements, we will invoke innovations to reduce beam hardening and to make reliable flow esti- mates. Currently, CT perfusion is done on different CT machines with manufacturers’ proprietary software, using algorithms that can give erroneous MBFs. Applicable to any commercial scanner; our solution would harmonize measurements across acquisition systems providing trustworthy, standardized measurements to clinicians, thereby improving management of cardiovascular patients.

独立于系统的心脏CT定量灌注 第二阶段，SBIR 摘要 BioInVision，Inc.和Team-Case西部储备大学(CWRU)生物医学工程师和大学 医院克利夫兰医学中心(UH)成像心脏病专家-将开发定量分析软件 心脏CT灌注(CCTP)数据，为评估心血管疾病创造了一个重要工具。使用 通过这一产品，心脏病专家将能够识别冠状动脉区域的功能性血流缺陷。当一个人 将功能性心肌血流量(MBF)功能与冠状动脉解剖相结合，从冠状动脉计算机到 放射血管造影术(CCTA)，它提供关于狭窄的生理意义的必要信息。 CCTP+CCTA的组合可以提供一个理想的门槛检查来决定是否将患者送往 经皮有创冠状动脉造影术和潜在的干预(例如，支架植入)。此外，低流量与- 狭窄的存在表明微血管疾病，这是一种越来越令人担忧的非常普遍的疾病， 尤其是在女性和糖尿病患者中。与所有其他非侵入性心血管疾病相比，CT更具优势 成像技术(SPECT、PET和MRI)。它在许多环境中都可以使用，包括急诊科， 并且与其他方法相比具有较高的吞吐量。它提供MBF和可靠的冠状动脉解剖， 在任何其他单一模式中都不可用，提供了一种独特的非侵入性区分心脏 微血管疾病。它具有出色的分辨率，能够检测到心内膜灌注不足，被认为 成为SPECT无法评估的早期疾病指标。CT更便宜，患者也更多 吞吐量比核磁共振或正电子发射计算机断层扫描要好。随着MBF的加入，CT将有一个极好的机会来颠覆 引导经皮介入的诊断途径，这是一条由SPECT主导的途径。 心脏成像，一种提供关于冠状动脉解剖的零信息的方式。要做到可靠、准确 CT MBF测量，我们将利用创新来减少射束硬化并做出可靠的流动测试- 伙计们。目前，CT灌注是在不同的CT机上进行的，使用制造商的专有软件，使用 可能会给出错误的MBF的算法。适用于任何商用扫描仪；我们的解决方案将协调 跨采集系统的测量为临床医生提供可靠、标准化的测量， 从而改善对心血管病人的管理。